All NewsFDA BriefsOncology IconsSpecial ReportsVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPivotal Practice Views with the Oncology BrothersPodcastsPrecision Medicine
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CME/CE
Case-Based Roundtable SeriesClinical TrialsPartnersPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
eNewsletterPrint Subscription
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2-Positive Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CME/CE
Advertisement

A 70-Year-Old Woman with Newly Diagnosed Chronic Lymphocytic Leukemia : Episode 5

Case Review: Recommended Monitoring for Newly Diagnosed Chronic Lymphocytic Leukemia

Apr 18, 2022
John Allan, MD
Video

An expert in hematologic malignancies describes how he would monitor a patient on frontline treatment with newly diagnosed chronic lymphocytic leukemia.

EP: 1.Case Presentation: A 70-Year-Old Woman with Newly Diagnosed Chronic Lymphocytic Leukemia

EP: 2.Ongoing Challenges in the Treatment of Frontline Chronic Lymphocytic Leukemia

EP: 3.Frontline Treatment Approaches in Patients with Chronic Lymphocytic Leukemia

EP: 4.Considering Comorbidities when Choosing a Chronic Lymphocytic Leukemia Treatment

Now Viewing

EP: 5.Case Review: Recommended Monitoring for Newly Diagnosed Chronic Lymphocytic Leukemia

EP: 6.Strategies for Managing Adverse Events when Treating Chronic Lymphocytic Leukemia

EP: 7.Novel Strategies and Treatments in Chronic Lymphocytic Leukemia

Case: A 70-Year-Old Woman with Newly Diagnosed Chronic Lymphocytic Leukemia

Initial Presentation:

  • A 70-year-old woman presented to her PCP for a routine checkup complaining of moderate, progressive fatigue and unintended weight loss over the last 4 months.
  • PMH: hypercholesterolemia (well controlled on medication; reports having a relatively healthy diet)
  • SH: Retired nurse; exercises at least 30 minutes per day most days of the week; enjoys spending time with her grandkids and traveling with her spouse; ~1-2 drinks in social settings per week
  • PE: vital signs WNL, right cervical lymphadenopathy~2.7 cm, spleen palpable 5 cm below costal margin, otherwise well-appearing
  • Laboratory findings:
    • WBC 186,000; 75% lymphocytes
    • Hb 9.4 g/dL
    • Platelets 85 X 109/L
  • Cr Cl: 61 ml/min
  • Flow cytometry; CD5+, CD19+, CD23+
  • beta2M, 3.8 mg/L
  • IGHV mutational status: unmutated; TP53 unmutated
  • ECOG PS 0
  • BM biopsy; diffuse infiltration by CLL

Treatment:

  • Options for treatment were reviewed and discussed with the patient, her spouse, and the care team.
  • The decision was made to initiate the patient on fixed duration venetoclax + obinutuzumab.
Related Videos
Expert on mUC
Expert on mUC
Expert on mUC
Expert on mUC
Expert on mUC
Expert on mUC
Expert on mUC
Expert on mUC
Related Content

Superior Outcomes Seen With Fixed-Duration Ibrutinib/Venetoclax in CLL

September 21st 2023

Exciting Activity in Chronic Lymphocytic Leukemia

May 31st 2023

CLL Investigators Look to Write the Next Chapter of BCL-2 Inhibition

September 8th 2023

Better Strategies for the Treatment of High-Risk Chronic Lymphocytic Leukemia

May 17th 2022

Ofatumumab-Based Regimens Improve Survival in CLL

August 28th 2023

FDA Clears Phase 3 Trial of Lisaftoclax in CLL/SLL

August 8th 2023

Superior Outcomes Seen With Fixed-Duration Ibrutinib/Venetoclax in CLL

September 21st 2023

Exciting Activity in Chronic Lymphocytic Leukemia

May 31st 2023

CLL Investigators Look to Write the Next Chapter of BCL-2 Inhibition

September 8th 2023

Better Strategies for the Treatment of High-Risk Chronic Lymphocytic Leukemia

May 17th 2022

Ofatumumab-Based Regimens Improve Survival in CLL

August 28th 2023

FDA Clears Phase 3 Trial of Lisaftoclax in CLL/SLL

August 8th 2023

Superior Outcomes Seen With Fixed-Duration Ibrutinib/Venetoclax in CLL

September 21st 2023

Exciting Activity in Chronic Lymphocytic Leukemia

May 31st 2023

CLL Investigators Look to Write the Next Chapter of BCL-2 Inhibition

September 8th 2023

Better Strategies for the Treatment of High-Risk Chronic Lymphocytic Leukemia

May 17th 2022

Ofatumumab-Based Regimens Improve Survival in CLL

August 28th 2023

FDA Clears Phase 3 Trial of Lisaftoclax in CLL/SLL

August 8th 2023
Related Content
Advertisement

Superior Outcomes Seen With Fixed-Duration Ibrutinib/Venetoclax in CLL

Superior Outcomes Seen With Fixed-Duration Ibrutinib/Venetoclax in CLL

September 21st 2023
Article

In the phase 3 GLOW study, ibrutinib plus venetoclax significantly improved progression-free survival and other outcomes in patients with chronic lymphocytic leukemia, across most genomic subgroups.

Read More


Exciting Activity in Chronic Lymphocytic Leukemia

Exciting Activity in Chronic Lymphocytic Leukemia

May 31st 2023
Podcast

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Listen


CLL Investigators Look to Write the Next Chapter of BCL-2 Inhibition

CLL Investigators Look to Write the Next Chapter of BCL-2 Inhibition

September 8th 2023
Article

Venetoclax has given new hope and better options to a notoriously hard-to-treat patient group.

Read More


Better Strategies for the Treatment of High-Risk Chronic Lymphocytic Leukemia

Better Strategies for the Treatment of High-Risk Chronic Lymphocytic Leukemia

May 17th 2022
Podcast

In season 3, episode 4 of Targeted Talks, Alexey Danilov, MD, PhD, discusses the shift toward utilizing cellular therapy to treat high-risk patients with chronic lymphocytic leukemia.

Listen


Ofatumumab-Based Regimens Improve Survival in CLL

Ofatumumab-Based Regimens Improve Survival in CLL

August 28th 2023
Article

Combination therapies utilizing ofatumumab could improve outcomes for patients with chronic lymphocytic leukemia, according to an analysis published in the Annals of Hematology.

Read More


FDA Clears Phase 3 Trial of Lisaftoclax in CLL/SLL

FDA Clears Phase 3 Trial of Lisaftoclax in CLL/SLL

August 8th 2023
Article

Lisaftoclax is a novel, orally administered small-molecule BCL-2 selective inhibitor. A study of the agent in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma will commence in the second half of 2023.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Contact Info

2 Clarke Drive
Cranbury, NJ 08512

609-716-7777

© 2023 MJH Life Sciences

All rights reserved.